Related Experiment Videos
Transforming growth factor betas and their receptors in human liver cirrhosis
H U Baer1, H Friess, M Abou-Shady
1Department of Visceral and Transplantation Surgery, University of Bern, Switzerland.
Background:
Transforming growth factor betas (TGF-betas) are a group of homologous polypeptides that exert pleiotropic effects on various cell types and stimulate the formation of extracellular matrix and fibrosis. To evaluate whether TGF-beta isoforms (TGF-beta1, TGF-beta2 and TGF-beta3) and their receptors (types I-III) are also of importance in the pathophysiology of liver cirrhosis, we analysed their concomitant expression and localization in human liver cirrhosis.
Patients:
Cirrhotic liver tissue samples were obtained from 17 patients (four women, 13 men) with a median age of 41 years (range 22-67). Normal liver tissues from ten patients (seven women, three men) with a median age of 55 years (range 45-75) served as controls.
Methods:
The tissues were fixed in Bouin's solution and paraffin-embedded for histological analysis. For RNA analysis, freshly obtained tissue samples were snap-frozen in liquid nitrogen and stored at -80 degrees C until analysed. Northern blot analysis was used to examine the expression of TGF-beta1, beta2 and beta3 and their receptors, type I (TbetaR-I), type II (TbetaR-II) and type III (TbetaR-III). Immunohistochemistry was performed to determine the localization of the corresponding proteins in the normal and the cirrhotic liver.
Results:
Northern blot analysis revealed enhanced expression (P < 0.05) of TGF-beta1 (twofold increase), TGF-beta2 (threefold increase) and TGF-beta3 (8.5-fold increase) and of TbetaR-II (threefold increase) mRNA in liver cirrhosis in comparison with normal controls. In contrast, TbetaR-I (ALK-5) and TbetaR-III mRNA expression showed no significant changes. No TGF-beta isoform immunoreactivity was present in hepatocytes in either normal livers or in liver cirrhosis. However, in liver cirrhosis, intense TGF-beta1 immunoreactivity was present in bile duct and ductular epithelial cells (including ductular proliferations) and in inflammatory cells. In a few sinusoidal lining cells, faint TGF-beta1 and moderate TGF-beta2 immunoreactivity was present. TGF-beta3 immunostaining was present in bile duct and ductular epithelial cells, in inflammatory cells and in fibroblast-like spindle cells in liver cirrhosis. For TbetaR-I and TbetaR-II, the immunoreactivity was localized in hepatocytes and biliary cells in normal and cirrhotic liver tissues, with higher intensity for TbetaR-II in the cirrhotic liver.
Conclusion:
Enhanced expression of all three TGF-bea isoforms and of TbetaR-II in liver cirrhosis suggests their involvement in this fibrotic disorder. The higher immunoreactivity of the three TGF-beta isoforms in the bile duct epithelial cells in cirrhotic tissues suggests a possible role of these cells in the pathogenesis of liver cirrhosis.
Insights
Transforming growth factor betas (TGF-betas) and their receptor type II (TbetaR-II) show increased expression in liver cirrhosis. Bile duct epithelial cells in cirrhotic livers may play a role in this fibrotic disorder.
Area of Science:
- Cell Biology
- Molecular Biology
- Pathophysiology
Background:
- Transforming growth factor betas (TGF-betas) are polypeptides that promote extracellular matrix formation and fibrosis.
- The role of TGF-beta isoforms and their receptors in liver cirrhosis pathophysiology requires investigation.
Purpose of the Study:
- To analyze the expression and localization of TGF-beta isoforms (TGF-beta1, TGF-beta2, TGF-beta3) and their receptors (types I-III) in human liver cirrhosis.
- To determine the potential involvement of these factors in the fibrotic process of liver cirrhosis.
Main Methods:
- Analysis of liver tissue samples from 17 patients with cirrhosis and 10 healthy controls.
- Northern blot analysis to assess mRNA expression of TGF-beta isoforms and receptors.
- Immunohistochemistry to determine protein localization in normal and cirrhotic liver tissues.
Main Results:
- Significantly enhanced mRNA expression of TGF-beta1 (2-fold), TGF-beta2 (3-fold), TGF-beta3 (8.5-fold), and TbetaR-II (3-fold) in liver cirrhosis compared to controls.
- No significant changes in TbetaR-I and TbetaR-III mRNA expression.
- TGF-beta isoforms were localized in bile duct epithelial cells, inflammatory cells, and fibroblast-like cells in cirrhotic livers, with no immunoreactivity in hepatocytes. TbetaR-I and TbetaR-II were found in hepatocytes and biliary cells, with higher TbetaR-II intensity in cirrhosis.
Conclusions:
- Elevated expression of TGF-beta isoforms and TbetaR-II in liver cirrhosis indicates their involvement in the fibrotic disorder.
- The increased presence of TGF-beta isoforms in bile duct epithelial cells suggests a potential role for these cells in the pathogenesis of liver cirrhosis.